---

---

nvl-520  

save search

---

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
NUVL | $62.71 -0.56% -0.56% 1.2M |

| -10.6% | O: 0.01% H: 0.0% C: -2.52%
nvl-330 preclinical meeting

---

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| -22.92% | O: 0.92% H: 3.14% C: 2.8%
nvl-330 preclinical meeting

---

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
NUVL | $62.71 -0.56% -0.56% 1.2M |

| -27.54% | O: 1.49% H: 1.65% C: 1.24%
nvl-520 fda designation therapy

---

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
Published: 2022-12-13 (Crawled : 19:00) - biospace.com/
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 105.37% | O: 3.17% H: 1.54% C: -1.3%
nvl-520 cancer publication

---

Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC
Published: 2022-10-28 (Crawled : 05:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 185.27% | O: 42.89% H: 0.0% C: 0.0%
nvl-520 trial potential phase 1

---

Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
Published: 2022-10-26 (Crawled : 11:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 222.18% | O: 0.1% H: 2.18% C: -2.1%
nvl-330 preclinical nvl-655

---

Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
Published: 2022-10-17 (Crawled : 11:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 202.75% | O: 1.3% H: 5.71% C: 5.62%
nvl-520 conference preclinical symposium trial

---

Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
Published: 2022-07-13 (Crawled : 11:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 272.02% | O: -2.19% H: 10.67% C: 7.76%
nvl-655 nvl-520 conference preclinical meeting trial cancer pre-clinical

---

Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
Published: 2022-06-21 (Crawled : 11:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 530.44% | O: 5.47% H: 0.0% C: 0.0%
nvl-520

---

Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 18:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 395.73% | O: -0.47% H: 11.11% C: 4.37%
nvl-520 preclinical pre-clinical

---

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
Published: 2022-03-08 (Crawled : 23:00) - prnewswire.com
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 294.72% | O: 2.01% H: 7.27% C: -2.9%
nvl-520 preclinical pre-clinical

---

Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
Published: 2022-01-07 (Crawled : 13:00) - biospace.com/
NUVL | $62.71 -0.56% -0.56% 1.2M |

| 230.06% | O: -23.9% H: 0.0% C: 0.0%
nvl-520 trial phase 1

---

Gainers vs Losers

67%

33%

Top 10 Gainers

GBR | $1.42 31.48% 11.27% 990K |

Energy Minerals

KUKE | $2.88 2.49% 7.64% 360K |

MPLN | $0.6502 -11.74% 4.51% 2.2M |

Finance

CXM 4 | $11.34 -0.44% 4.27% 1.7M |

Information

PVL 4 | $1.47 -0.68% 4.08% 77K |

Energy Minerals

RNR 4 | $224.74 0.85% 3.52% 310K |

Finance

PZG | $0.4431 0.48% 2.91% 150K |

Non-Energy Minerals

LEV | $0.972 0.73% 2.88% 570K |

Manufacturing

DBRG | $17.3 0.06% 1.97% 1.2M |

Finance and Insurance

OSK 4 | $117.72 0.05% 1.96% 370K |

Producer Manufacturing

---

Your saved searches

---